North America
South America
Australia & New Zealand
Europe
Middle East / Africa
Asia / Pacific
×
×
Purified Mouse Anti- PKA [RI] 18/PKA [RI] RUO

Purified Mouse Anti- PKA [RI] 

Clone  18/PKA [RI]   (RUO)

  • Brand BD Transduction Laboratories™
  • Concentration 250 µg/ml
  • Isotype Mouse IgG2b
  • Reactivity Human (QC Testing)  Mouse, Rat, Dog, Chicken, Frog (Tested in Development) 
  • Application Western blot (Routinely Tested) 
    Bioimaging, Immunoprecipitation (Tested During Development) 
  • Immunogen Mouse PKA [RI] subunit aa. 225-381
  • Storage Buffer Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium azide.
  • Regulatory Status RUO
Product Details Recommended Assay References

Description

cAMP-dependent Protein Kinase (PKA) is composed of two distinct subunits: catalytic (C) and regulatory (R). Four regulatory subunits have been identified: RIα, RIß, RIIα, and RIIß. These subunits define type I and II cAMP-dependent protein kinases. Following binding of cAMP, the regulatory subunits dissociate from the catalytic subunits, rendering the enzyme active. Type I and type II holoenzymes have three potential C subunits (Cα, Cß, or Cγ). Type II PKA can be distinguished by autophosphorylation of the R-subunits, while type I PKA binds Mg/ATP with high affinity. Most cells express both type I and type II PKAs. Although the Rα isoforms are ubiquitously expressed, the Rß isoforms are predominant in nervous and adipose tissues. The levels of expression of the different subunits vary according to cell and tissue type.

Format
  • Format Purified

Other Formats →

Suggested Companion Products

FITC Goat Anti-Mouse Ig Polyclonal RUO
0.5 mg Cat No: 554001

Human Endothelial Cell Lysate RUO
500 µg Cat No: 611450

HRP Goat Anti-Mouse Ig RUO
1 mL Cat No: 554002

Fixation Buffer RUO
100 mL Cat No: 554655

Perm Buffer III RUO
125 mL Cat No: 558050

Stain Buffer (FBS) RUO
500 mL Cat No: 554656

Resources & Tools
 Spectrum Viewer  Download TDS  Regulatory Document Website
Preparation and Storage

Store undiluted at -20°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
  3. This antibody has been developed and certified for the bioimaging application. However, a routine bioimaging test is not performed on every lot. Researchers are encouraged to titrate the reagent for optimal performance.
  4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  5. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
  6. Triton is a trademark of the Dow Chemical Company.


Bioimaging

1. Seed the cells in appropriate culture medium at ~10,000 cells per well in a BD Falcon™ 96-well Imaging Plate (Cat. No. 353219) and culture overnight.

2. Remove the culture medium from the wells, and fix the cells by adding 100 μl of BD Cytofix™ Fixation Buffer (Cat. No. 554655) to each well. Incubate for 10 minutes at room temperature (RT).

3. Remove the fixative from the wells, and permeabilize the cells using either BD Perm Buffer III, 90% methanol, or Triton™ X-100:

a. Add 100 μl of -20°C 90% methanol or Perm Buffer III (Cat. No. 558050) to each well and incubate for 5 minutes at RT.

OR

b. Add 100 μl of 0.1% Triton™ X-100 to each well and incubate for 5 minutes at RT.

4. Remove the permeabilization buffer, and wash the wells twice with 100 μl of 1× PBS.

5. Remove the PBS, and block the cells by adding 100 μl of BD Pharmingen™ Stain Buffer (FBS) (Cat. No. 554656) to each well. Incubate for 30 minutes at RT.

6. Remove the blocking buffer and add 50 μl of the optimally titrated primary antibody (diluted in Stain Buffer) to each well, and incubate for 1 hour at RT.

7. Remove the primary antibody, and wash the wells three times with 100 μl of 1× PBS.

8. Remove the PBS, and add the second step reagent at its optimally titrated concentration in 50 μl to each well, and incubate in the dark for 1 hour at RT.

9. Remove the second step reagent, and wash the wells three times with 100 μl of 1× PBS.

10. Remove the PBS, and counter-stain the nuclei by adding 200 μl per well of 2 μg/ml Hoechst 33342 (e.g., Sigma-Aldrich Cat. No. B2261) in 1× PBS to each well at least 15 minutes before imaging.

11. View and analyze the cells on an appropriate imaging instrument.

Bioimaging: For more detailed information please refer to http://www.bdbiosciences.com/support/resources/protocols/ceritifed_reagents.jsp

Western blot: For more detailed information please refer to http://www.bdbiosciences.com/pharmingen/protocols/Western_Blotting.shtml


  1. Chen W, Yu YL, Lee SF, et al. CREB is one component of the binding complex of the Ces-2/E2A-HLF binding element and is an integral part of the interleukin-3 survival signal. Mol Cell Biol. 2001; 21(14):4636-4646. View reference

  2. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res. 1990; 50(22):7093-7100. View reference

  3. Dohrman DP, Diamond I, Gordon AS. Ethanol causes translocation of cAMP-dependent protein kinase catalytic subunit to the nucleus. Proc Natl Acad Sci U S A. 1996; 93(19):10217-10221. View reference

  4. Orellana SA, Marfella-Scivittaro C. Distinctive cyclic AMP-dependent protein kinase subunit localization is associated with cyst formation and loss of tubulogenic capacity in Madin-Darby canine kidney cell clones. J Biol Chem. 2000; 275(28):21233-21240. View reference

  5. Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem. 1990; 59:971-1005. View reference

610165 Rev.
Instruments
Reagents
Applications
Sales & Support
BD BioSciences